Paul H. Trienekens

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

Loes E. Visser, Ron HN van Schaik, M. van Vliet et al. · Thrombosis and Haemostasis · 2004 · 90 citations

Medicine, Pharmacokinetics, Pharmacology +15

Screening for metabolic vitamin B ₁₂ deficiency by holotranscobalamin in patients suspected of vitamin B ₁₂ deficiency: a multicentre study

Sandra G. Heil, Róbert de Jonge, Maurits C. F. J. de Rotte et al. · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · 2012 · 88 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +14

The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants

Loes E. Visser, Gysèle S. Bleumink, Paul H. Trienekens et al. · British Journal of Haematology · 2004 · 65 citations · Full text

Medicine, Cardiology, Pharmacology +13

Patients with an ApoE ϵ4 allele require lower doses of coumarin anticoagulants

Loes E. Visser, Paul H. Trienekens, Peter A. G. M. De Smet et al. · Pharmacogenetics and Genomics · 2005 · 61 citations

Medicine, Genetics, Pharmacotherapy +15

Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants

Loes E. Visser, R VANSCHAIK, M VANVLIET et al. · Clinical Pharmacology & Therapeutics · 2005 · 51 citations

Veterinary Medicine, Pharmacology, Clinical Pharmacology +10